The Role of Steroids Following Selective Laser Trabeculoplasty

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00406042
Recruitment Status : Completed
First Posted : December 4, 2006
Last Update Posted : March 29, 2007
Information provided by:
West Virginia University

Brief Summary:
To evaluate whether or not using topical steroids after selective laser trabeculoplasty affects intraocular pressure outcomes.

Condition or disease Intervention/treatment Phase
Glaucoma Drug: prednisolone acetate 1% Not Applicable

Detailed Description:
Subjects undergoing bilateral SLT will be randomly assigned to use prednisolone acetate 1% in one eye four times daily with no treatment in the fellow eye, for one week following SLT. Examinations will occur at baseline, and one week, one month and three months after SLT. IOP and anterior chamber inflammation will be noted at each visit.

Study Type : Interventional  (Clinical Trial)
Enrollment : 25 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single
Primary Purpose: Treatment
Official Title: The Role of Topical Prednisolone Acetate Following Selective Laser Trabeculoplasty
Study Start Date : September 2005
Actual Study Completion Date : June 2006

Primary Outcome Measures :
  1. Intraocular pressure reduction

Secondary Outcome Measures :
  1. Anterior chamber inflammation

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • glaucoma or ocular hypertension
  • need for bilateral SLT

Exclusion Criteria:

  • eye disease precluding accurate IOP measurement
  • contraindication to topical prednisolone acetate

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00406042

United States, West Virginia
West Virginia University Eye Institute
Morgantown, West Virginia, United States, 26505
Sponsors and Collaborators
West Virginia University
Principal Investigator: Tony Realini, MD West Virginia University Eye Institute

Publications automatically indexed to this study by Identifier (NCT Number): Identifier: NCT00406042     History of Changes
Other Study ID Numbers: 16678
First Posted: December 4, 2006    Key Record Dates
Last Update Posted: March 29, 2007
Last Verified: March 2007

Keywords provided by West Virginia University:

Additional relevant MeSH terms:
Ocular Hypertension
Eye Diseases
Prednisolone acetate
Methylprednisolone acetate
Methylprednisolone Hemisuccinate
Prednisolone hemisuccinate
Prednisolone phosphate
Anti-Inflammatory Agents
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Antineoplastic Agents, Hormonal
Antineoplastic Agents
Autonomic Agents
Peripheral Nervous System Agents
Gastrointestinal Agents
Neuroprotective Agents
Protective Agents